GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (STU:L1PA) » Definitions » Inventory-to-Revenue

Lee's Pharmaceutical Holdings (STU:L1PA) Inventory-to-Revenue : 0.40 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lee's Pharmaceutical Holdings Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Lee's Pharmaceutical Holdings's Average Total Inventories for the quarter that ended in Jun. 2024 was €31.0 Mil. Lee's Pharmaceutical Holdings's Revenue for the six months ended in Jun. 2024 was €78.3 Mil. Lee's Pharmaceutical Holdings's Inventory-to-Revenue for the quarter that ended in Jun. 2024 was 0.40.

Lee's Pharmaceutical Holdings's Inventory-to-Revenue for the quarter that ended in Jun. 2024 declined from Dec. 2023 (0.58) to Dec. 2023 (0.40)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Lee's Pharmaceutical Holdings's Days Inventory for the six months ended in Jun. 2024 was 154.57.

Inventory Turnover measures how fast the company turns over its inventory within a year. Lee's Pharmaceutical Holdings's Inventory Turnover for the quarter that ended in Jun. 2024 was 1.18.


Lee's Pharmaceutical Holdings Inventory-to-Revenue Historical Data

The historical data trend for Lee's Pharmaceutical Holdings's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lee's Pharmaceutical Holdings Inventory-to-Revenue Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventory-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 0.29 0.28 0.23 0.26

Lee's Pharmaceutical Holdings Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.44 0.57 0.58 0.40

Competitive Comparison of Lee's Pharmaceutical Holdings's Inventory-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lee's Pharmaceutical Holdings's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lee's Pharmaceutical Holdings's Inventory-to-Revenue falls into.



Lee's Pharmaceutical Holdings Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Lee's Pharmaceutical Holdings's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Inventory-to-Revenue (A: Dec. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )
=( (30.219 + 35.003) / 2 ) / 123.644
=32.611 / 123.644
=0.26

Lee's Pharmaceutical Holdings's Inventory-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Inventory-to-Revenue (Q: Jun. 2024 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Dec. 2023 ) + Total Inventories (Q: Jun. 2024 )) / count ) / Revenue (Q: Jun. 2024 )
=( (35.003 + 27.006) / 2 ) / 78.31
=31.0045 / 78.31
=0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lee's Pharmaceutical Holdings  (STU:L1PA) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Lee's Pharmaceutical Holdings's Days Inventory for the six months ended in Jun. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Jun. 2024 )/Cost of Goods Sold (Q: Jun. 2024 )*Days in Period
=31.0045/36.607*365 / 2
=154.57

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Lee's Pharmaceutical Holdings's Inventory Turnover for the quarter that ended in Jun. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2024 ) / Average Total Inventories (Q: Jun. 2024 )
=36.607 / 31.0045
=1.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lee's Pharmaceutical Holdings Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lee's Pharmaceutical Holdings Business Description

Traded in Other Exchanges
Address
Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.

Lee's Pharmaceutical Holdings Headlines

No Headlines